Life Sciences Business Development Plan 2027: Why Q4 Is Not Too Late

Imen Jelassi

Oct 19

8 min read

A life sciences business development plan 2027 is a one-page document that sets a revenue target, converts it into the pipeline and meetings required to hit it, names the accounts and demand signals you will pursue, and assigns owners and dates. CROs, CDMOs and pharma service providers that write it in Q4 reach sponsors while next year's budgets are still being shaped. Corstrate builds these plans for life sciences service companies.

Author: Imen Jelassi, Founder, Corstrate, Life Sciences Business Development Consultant

Key Takeaways

Q4 is planning season, not dead season. Sponsors lock next year's program budgets and vendor shortlists in the final quarter, so outreach now is positioned ahead of the RFP, not behind it.
Start with coverage math, not tactics. A 20% win rate needs roughly 5x pipeline coverage, and a 25% win rate roughly 4x (Abmatic, 2026). Work backward from revenue to meetings per month before choosing a channel.
Plan around three demand signals. Biologics and advanced modalities, integrated end-to-end partnerships, and reshoring all shape where sponsors will spend in 2027.
Speed and capacity beat price. Sponsors have ranked on-time delivery and capacity availability above cost as top CDMO decision drivers for four consecutive years (Pharmaceutical Online, 2026). Say so in your plan and your messaging.
One page is enough. A plan that fits on one page gets used. The template at the end of this guide covers target, coverage, accounts, signals, owners and a 30/60/90 review.

Worked example of a 2027 life sciences BD plan: $3M target, 60 qualified opportunities, 5x pipeline coverage, 12 meetings a month.

Why Q4 is the best time to plan 2027 business development

Many service providers treat the last six weeks of the year as a write-off. Sponsors do not. Annual budgets are being finalized, programs for the next year are being sequenced, and vendor shortlists are being refreshed before the new fiscal cycle opens. If your first conversation with a sponsor happens in February, the shortlist may already exist.

The backdrop supports acting early. According to William Blair analysts cited by Pharma Manufacturing, biopharma raised about $70.7 billion in 2025, and Q4 2025 alone reached about $26.8 billion, the highest quarterly total since Q4 2021 (Pharma Manufacturing, 2026). Evaluate Pharma, cited in the same piece, forecasts total biopharma R&D spending to grow about 4% in both 2026 and 2027. That is steady growth, not a boom, which is exactly why a disciplined plan matters: the money is there, but sponsors are selective.

Timing also matters inside the sponsor. One sales-intelligence analysis of CRO and CDMO prospecting describes the opening as the six to nine months before an RFP is written, and notes that sponsors issue RFPs to a pre-qualified shortlist rather than the open market (Salesmotion, 2026). A cold bid at RFP time is, in that framing, a courtesy bid. Q4 outreach is how you get onto the list before the RFP exists. For the RFP stage itself, see our guide on how to get on a pharma preferred vendor list.

If you ran the mid-year review we described in the H2 2026 priorities check-in, this guide is the sequel: it turns what you learned into next year's plan.

What does a life sciences business development plan 2027 need to contain?

A workable life sciences business development plan 2027 has six parts. Anything beyond them is usually decoration.

A revenue target split into new-logo revenue and expansion revenue from existing clients.
Coverage math that converts the new-logo target into qualified pipeline, opportunities and meetings per month.
An account list of named target sponsors, ranked in tiers, with a reason each one is on the list.
Demand signals you will use to time outreach (funding, phase transitions, capacity announcements, M&A).
Owners and cadence, meaning who runs outreach, who owns the CRM, and when the plan is reviewed.
Leading indicators you will track at 30, 60 and 90 days, so you know by March whether the plan is working.

Build the plan backward from revenue

Start from the number the business needs, then work down. The sequence is: target new revenue, average deal size, required wins, win rate, qualified opportunities needed, pipeline value needed, and meetings per month. Every step uses an assumption from your own history, and the plan is only as honest as those assumptions.

The pipeline coverage math, with a worked example

Pipeline coverage is qualified open pipeline divided by the revenue target. The older 3x rule of thumb dates from a period when mature funnels closed roughly 25 to 33% of qualified pipeline. More recent commentary puts post-2022 win rates closer to 18 to 22%, which pushes the needed coverage to about 4x to 5x (Abmatic, 2026). Treat these as rough bands: the source itself notes there is no single authoritative number, and your own win rate matters more than any benchmark.

Worked example (illustrative assumptions, replace with your own):

Step	Assumption	Result
New-logo revenue target for 2027	Set by the business	$3,000,000
Average first-year deal value	From your last 12 months	$250,000
Wins required	$3,000,000 / $250,000	12 wins
Win rate on qualified opportunities	Your own history	20%
Qualified opportunities needed	12 / 0.20	60 opportunities
Pipeline value needed	60 x $250,000	$15,000,000 (5x coverage)
First meeting to qualified opportunity rate	Your own history	40%
First meetings needed	60 / 0.40	150 meetings
Meetings per month	150 / 12	About 12 to 13

Roughly a dozen first meetings a month is a very different planning problem from "win more business." It tells you how many accounts you must contact, how many reply, and how much BD capacity you need. If you do not have that capacity internally, that is the point at which a fractional business development model becomes a real option. For a deeper look at building the funnel itself, read our guide to pipeline optimization in life sciences.

One caution on sales cycles: in life sciences services, the time from first meeting to signed work often spans many months, so meetings booked in Q1 may not become revenue until late 2027. If your target is revenue recognized in 2027, you need to start now. That is the practical argument for Q4 planning.

Three 2027 demand signals to plan around

1. Biologics and advanced modalities

Biologics and sterile injectables are under the most capacity pressure. One 2026 CDMO forecast notes that more than 400 antibody-drug conjugates are in development globally, and recommends sponsors begin CDMO engagement roughly 6 to 8 months before an intended start date (Pharmaceutical Online, 2026). For a CDMO with biologics or ADC capability, that lead time is your outreach window. For a CRO, the same pipeline of complex modalities drives specialized analytical and clinical demand.

2. Integrated, partnership-style engagements

The same forecast describes sponsors wanting long-term, multi-phase relationships rather than transactional work, which helps a CDMO forecast staff, materials and suite availability. For BD, this changes the pitch: lead with the continuity of development through manufacturing, tech transfer readiness and a named team, not a price list. Our article on how sponsors actually choose a CDMO shows the scorecard sponsors use.

3. Reshoring and supply resilience

US onshoring is increasing, mainly in oral solid dose and small-molecule API, while biologics and sterile injectables continue to rely heavily on global CDMOs (same source). Large pharma is also adding its own capacity: the 2025 announcements listed in that forecast, from AstraZeneca, Merck, GSK, Amgen, Novartis, Roche/Genentech and AbbVie, total roughly $7 billion. The article notes this insourcing mainly affects later-stage work, while most biotechs keep using CDMOs in Phases 1 and 2. The planning implication: weight your account list toward emerging and mid-size sponsors, and have a clear answer on geography and supply continuity.

Which BD approach fits your 2027 plan?

Approach	Best for	Strength	Watch out for
Founder-led selling with a system	Under about 30 staff, referral-driven	Credibility, low cost	Founder time is the bottleneck
Junior BD rep plus external strategy	30 to 100 staff, clear ICP	Capacity at moderate cost	Needs a defined process and coaching
Fractional BD	Service providers needing strategy plus execution fast	Senior judgment, flexible commitment	Needs a clear scope and KPIs
Full-time BD leader	Larger firms with proven pipeline	Full ownership	Cost and ramp time; risky before the system exists

If you are weighing the middle two options, our predictable pipeline guide for small CROs walks through the trade-offs in detail.

Q4 outreach: what to do in the next six weeks

Week 1: Finalize the revenue target and run the coverage math above.
Week 2: Build the tiered account list (Tier 1 about 25 accounts, Tier 2 about 75, Tier 3 the rest) and attach a signal to each. See pharmaceutical lead generation for list-building methods.
Weeks 3 and 4: Launch outbound to Tier 1 and Tier 2 with problem-led messages (capacity, timeline, tech transfer risk), not a capabilities brochure.
Week 5: Follow up on every conference contact still open. Our conference follow-up system covers the 48-hour to 90-day sequence.
Week 6: Review reply and meeting rates against the plan, and adjust before the year-end slowdown.

Holiday-week email volume drops, which can mean less competition in the inbox. Keep messages short and specific, and avoid the last two days before the break.

One-page life sciences BD plan template for 2027

Copy this into a document and fill in each line.

Revenue target (new logos): $____ | Expansion target: $____
Average deal value: $____ | Win rate: ____% | Coverage needed: ____x
Qualified opportunities needed: ____ | First meetings per month: ____
Tier 1 accounts (25): list, with the signal for each
Tier 2 accounts (75): list or segment definition
Primary demand signals this year: (for example funding, phase transitions, capacity announcements, M&A)
Offer and message: the one problem you solve, in one sentence
Channels and owners: outbound, LinkedIn, conferences, referrals, with a named owner each
CRM stages: the minimum set (target, contacted, meeting held, qualified, proposal, won or lost)
Day 30 / 60 / 90 indicators: accounts contacted, reply rate, meetings held, qualified opportunities created
Review date: first Monday of each month

Frequently asked questions

When should a CRO or CDMO start planning business development for 2027?

Start in Q4 of the current year. Sponsors finalize next-year budgets and refresh vendor shortlists late in the year, and service sales cycles are long, so meetings booked in Q4 and Q1 are what produce revenue later in 2027.

How much pipeline coverage does a life sciences service company need?

It depends on your win rate. Roughly, a 20% win rate needs about 5x coverage and a 25% win rate about 4x. Use your own historical win rate, and treat published benchmarks as rough guides.

What should a life sciences business development plan include?

A revenue target, coverage math, a tiered account list, the demand signals that time your outreach, named owners, and 30/60/90-day indicators. It should fit on one page so the team actually uses it.

Is Q4 a bad time to run outbound outreach to pharma and biotech?

No. Sponsors are planning next year's programs and vendors, so outreach in Q4 can reach them before shortlists are set. Avoid only the final days before the holidays, when response rates fall.

Should a small CRO or CDMO hire a BD lead or use fractional BD for 2027?

If you already have a proven pipeline process, a full-time hire can work. If you do not, a fractional model lets you build the system and test the market first. See our comparison of fractional BD versus hiring in-house.